GOSS

Company Overview — What Does Gossamer Bio, Inc. Do?

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California. Gossamer Bio, Inc. (GOSS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Faheem Hasnain and employs approximately 180 people. With a market capitalization of $86M, GOSS is one of the notable companies in the Healthcare sector.

Gossamer Bio, Inc. (GOSS) Stock Rating — Avoid (April 2026)

As of April 2026, Gossamer Bio, Inc. receives a Avoid rating with a composite score of 17.1/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.GOSS ranks #4,438 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Gossamer Bio, Inc. ranks #840 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

GOSS Stock Price and 52-Week Range

Gossamer Bio, Inc. (GOSS) currently trades at $0.39. The stock gained $0.02 (5.7%) in the most recent trading session. The 52-week high for GOSS is $3.87, which means the stock is currently trading -89.9% from its annual peak. The 52-week low is $0.33, putting the stock 18.6% above its annual trough. Recent trading volume was 11.8M shares, indicating strong institutional interest and high liquidity.

Is GOSS Overvalued or Undervalued? — Valuation Analysis

Gossamer Bio, Inc. (GOSS) carries a value factor score of 13/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-sales ratio is 1.75x, compared to 1.66x for the average Healthcare stock.

At current multiples, Gossamer Bio, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Gossamer Bio, Inc. Profitability — ROE, Margins, and Quality Score

Gossamer Bio, Inc. (GOSS) earns a quality factor score of 10/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 1107.6%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at -73.7% versus the sector average of -33.1%.

On a margin basis, Gossamer Bio, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -359.2% (sector: -66.1%). Net profit margin stands at -347.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -86.1% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

GOSS Debt, Balance Sheet, and Financial Health

Gossamer Bio, Inc. has a debt-to-equity ratio of -241.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 3.28x, indicating strong short-term liquidity. Total debt on the balance sheet is $198M. Cash and equivalents stand at $9M.

GOSS has a beta of 1.64, meaning it is more volatile than the broader market — a $10,000 investment in GOSS would be expected to move 63.8% more than the S&P 500 on any given day. The stability factor score for Gossamer Bio, Inc. is 13/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Gossamer Bio, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Gossamer Bio, Inc. reported revenue of $44M and earnings per share (EPS) of $-0.21. Net income for the quarter was $-154M. Gross margin was 100.0%. Operating income came in at $-159M.

In Q3 2025, Gossamer Bio, Inc. reported revenue of $13M and earnings per share (EPS) of $-0.21. Net income for the quarter was $-48M. Revenue grew 40.2% year-over-year compared to Q3 2024. Operating income came in at $-49M.

In Q2 2025, Gossamer Bio, Inc. reported revenue of $11M and earnings per share (EPS) of $-0.17. Net income for the quarter was $-38M. Revenue grew -88.0% year-over-year compared to Q2 2024. Operating income came in at $-39M.

In Q1 2025, Gossamer Bio, Inc. reported revenue of $10M and earnings per share (EPS) of $-0.16. Net income for the quarter was $-37M. Operating income came in at $-37M.

Over the past 8 quarters, Gossamer Bio, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $44M. Investors analyzing GOSS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

GOSS Dividend Yield and Income Analysis

Gossamer Bio, Inc. (GOSS) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

GOSS Momentum and Technical Analysis Profile

Gossamer Bio, Inc. (GOSS) has a momentum factor score of 9/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 45/100 reflects moderate short selling activity.

GOSS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Gossamer Bio, Inc. (GOSS) ranks #840 out of 838 stocks based on the Blank Capital composite score. This places GOSS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing GOSS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full GOSS vs S&P 500 (SPY) comparison to assess how Gossamer Bio, Inc. stacks up against the broader market across all factor dimensions.

GOSS Next Earnings Date

No upcoming earnings date has been announced for Gossamer Bio, Inc. (GOSS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy GOSS? — Investment Thesis Summary

The quantitative profile for Gossamer Bio, Inc. suggests caution. The quality score of 10/100 flags below-average profitability. The value score of 13/100 indicates premium valuation. Momentum is weak at 9/100, a headwind for near-term performance. High volatility (stability score 13/100) increases portfolio risk.

In summary, Gossamer Bio, Inc. (GOSS) earns a Avoid rating with a composite score of 17.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on GOSS stock.

Related Resources for GOSS Investors

Explore more research and tools: GOSS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare GOSS head-to-head with peers: GOSS vs AZN, GOSS vs SLGL, GOSS vs VMD.